Inhibition of glutathione-related enzymes augments LPS-mediated cytokine biosynthesis: Involvement of an IκB/NF-κB-sensitive pathway in the alveolar epithelium

International Immunopharmacology

Volumn 2, Issue 11, 2002, Pages 1567-1583

  Haddad, John J ^a   Safieh Garabedian, Bared ^b   Saadé, Nayef E ^b   Lauterbach, Ryszard ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

BCNU; BSO; Cytokine; Glutathione; I B ; Immunopharmacology; Inflammation; NF B; Redox

Indexed keywords

BUTHIONINE SULFOXIMINE; CARMUSTINE; CYTOKINE; GLUTAMATE CYSTEINE LIGASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE); PROTEIN SUBUNIT; TUMOR NECROSIS FACTOR ALPHA; ANTIMETABOLITE; GLUTATHIONE; THIOL DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA DETERMINATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; IMMUNOMODULATION; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE TRANSLOCATION; LUNG ALVEOLUS; METABOLISM; PHYSIOLOGY; PREGNANCY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES; BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; CARMUSTINE; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HOMEOSTASIS; LIPOPOLYSACCHARIDES; NF-KAPPA B; OXIDATION-REDUCTION; PREGNANCY; PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE); PULMONARY ALVEOLI; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS; TRANSLOCATION, GENETIC;

EID: 0036801771     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00117-0     Document Type: Article

References (45)

1. Thompson A.B., Robbins R.A., Romberger D.J. Immunological functions of the pulmonary epithelium. Eur. Respir. J. 8:1985;127-149.
2. Pittet J.F., Wiener-Kronish J.P., Serikov V., Matthay M.A. Resistance of the alveolar epithelium to injury from septic shock in sheep. Am. J. Respir. Crit. Care Med. 151:1995;1093-1100.
3. Matuschak G.M., Lechner A.J. Targeting the alveolar epithelium in acute lung injury: keratinocyte growth factor and regulation of the alveolar epithelial barrier. Crit. Care Med. 24:1996;905-907.
4. Matthay M.A., Fukuda N., Frank J., Kallet R., Daniel B., Sakuma T. Alveolar epithelial barrier: role in lung fluid balance in clinical lung injury. Clin. Chest Med. 21:2000;477-490.
5. 2/ROS) dependent release of IL-1β, IL-6 and TNF-α: evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium. Cytokine. 13:2001;138-147.
6. Haddad J.J., Safieh-Garabedian B., Saadé N.E., Land S.C. Thiol regulation of pro-inflammatory cytokines reveals a novel immunopharmacological potential of glutathione in the alveolar epithelium. J. Pharmacol. Exp. Ther. 296:2001;996-1005.
7. Kelley J. Cytokines of the lung. Am. Rev. Respir. Dis. 141:1990;765-788.
8. Dinarello C.A. Pro-inflammatory cytokines. Chest. 118:2000;503-508.
9. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., KowaLczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition: I. Differential regulation of lipopolysaccharide-mediated pro-inflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300:2002;559-566.
10. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., KowaLczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition: II. Evidence for the involvement of an inhibitory-κB/nuclear factor-κB-sensitive pathway in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300:2002;567-576.
11. Haddad J.J. Glutathione depletion is associated with augmenting a pro-inflammatory signal: evidence for an antioxidant/pro-oxidant mechanism regulating cytokines in the alveolar epithelium. Cytokines Cell Mol. Ther. 6:2000;177-187.
12. 2-evoked regulation of HIF-1α and NF-κB in perinatal lung epithelium requires glutathione biosynthesis. Am. J. Physiol. Lung Cell Mol. Physiol. 278:2000;L492-L503.
13. Haddad J.J., Olver R.E., Land S.C. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity: evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J. Biol. Chem. 275:2000;21130-21139.
14. p38-dependent regulation of pro-inflammatory cytokine production. Biochem. Pharmacol. 63:2002;305-320.
15. Haddad J.J., Land S.C. Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-α biosynthesis. Br. J. Pharmacol. 135:2002;520-536.
16. Meister A. Glutathione metabolism and its selective modification. J. Biol. Chem. 263:1988;17205-17208.
17. Hayes J.D., McLellan L.I. Glutathione and glutathione-dependent enzymes represent a co-coordinately regulated defense against oxidative stress. Free Radic. Res. 31:1999;273-300.
18. Dröge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H.P.et al. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 8:1994;1131-1138.
19. Cantin A.M., Hubbard R.C., Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 139:1989;370-372.
20. 2 cells exposed to oxidative stress or glutathione depletion. Arch. Biochem. Biophys. 342:1997;126-133.
21. Bunnell E., Pacht E.R. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 148:1993;1174-1178.
22. Saugstad O.D. Bronchopulmonary dysplasia and oxidative stress: are we closer to an understanding of the pathogenesis of BPD? Acta Pediatr. 86:1997;1277-1282.
23. Roum J.H., Behld R., McElvancy N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 75:1993;2419-2424.
24. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:1986;705-716.
25. Baldwin A.S. The transcription factor NF-κB and human disease. J. Clin. Invest. 107:2001;3-6.
26. 193-195 receptor antagonism in the alveolar epithelium. Biochem. J. 355:2001;29-38.
27. Haddad J.J., Land S.C. The differential expression of apoptosis factors in the alveolar epithelium is redox sensitive and requires NF-κB (RelA)-selective targeting. Biochem. Biophys. Res. Commun. 271:2000;257-267.
28. Smith A.C., Boyd M.R. Preferential effects of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity. J. Pharmacol. Exp. Ther. 229:1984;658-663.
29. Vanhoefer U., Yin M.-B. Carbamoylation of glutathione reductase by N,N-bis-(2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem. Pharmacol. 53:1997;801-809.
30. He Y.-H., Xu Y., Kobune M., Wu M., Kelley M.R., Martin W.J. II Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells. Am. J. Physiol. Lung Cell Mol. Physiol. 282:2002;L50-L55.
31. Wong M., Wells P.G. Modulation of embryonic glutathione reductase and phenytoin teratogenicity by 1,3-bis-(2-chloroethyl)-1-nitrosourea. J. Pharmacol. Exp. Ther. 250:1989;336-342.
32. Sen C.K. Redox signaling and the merging therapeutic potential of thiol antioxidants. Biochem. Pharmacol. 55:1998;1747-1758.
33. Alder V., Yin Z., Tew K.D., Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 18:1999;6104-6111.
34. Griffith O.W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254:1979;7558-7560.
35. Schreck R., Baeuerle P.A. Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-κB. Methods Enzymol. 234:1994;151-163.
36. Sen C.K., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
37. Manna S.K., Tien-Kuo M., Aggarwal B.B. Over-expression of γ-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-κB and activator protein-1. Oncogene. 18:1999;4371-4382.
38. Lin A., Karin M. Is NF-κB the sensor of oxidative stress? FASEB J. 13:1999;1137-1143.
39. Schreck R., Meier B., Männel D.N., Dröge W., Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor-κB in intact cells. J. Exp. Med. 175:1992;1181-1194.
40. Arrigo A.P. Gene expression and the thiol redox state. Free Radic. Biol. Med. 27:1993;936-944.
41. Anderson M.T., Staal F.J., Gilter C., Herzenberg L.A. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11527-11531.
42. Brennan P., O'Neill L.A. 2-Mercaptoethanol restores the ability of nuclear factor-κB (NF-κB) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrrolidine dithiocarbamate (PDTC): evidence for oxidation of glutathione in the mechanism of inhibition of NF-κB by PDTC. Biochem. J. 320:1996;975-981.
43. Didonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M.A. Cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature. 388:1997;548-554.
44. Beg A.A., Finco T.S., Mantermet P.V., Baldwin A.S. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκB: a mechanism for NF-κB activation. Mol. Cell Biol. 13:1993;3301-3310.
45. Carter A.B., Knudtson K.L., Monick M.M., Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression: the role of TATA-binding protein (TBP). J. Biol. Chem. 274:1999;30858-30863.